These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35152540)

  • 21. Monitored COVID-19 mRNA vaccine second doses for people with adverse reactions after the first dose.
    Gallagher MC; Haessler S; Pecoy-Whitcomb E; Bayuk J
    Allergy Asthma Proc; 2022 Jan; 43(1):37-39. PubMed ID: 34983708
    [No Abstract]   [Full Text] [Related]  

  • 22. Delayed angioedema after administration of the severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine.
    Watts MM; Maurer LE; Grammer LC; Saltoun CA; Stevens WW
    Ann Allergy Asthma Immunol; 2022 Feb; 128(2):215-216. PubMed ID: 34699970
    [No Abstract]   [Full Text] [Related]  

  • 23. Incidence of Myocarditis after Messenger RNA Vaccine for COVID-19 in Young Male Recipients.
    Kato S; Horita N; Utsunomiya D
    Am J Cardiol; 2022 Jun; 172():159-161. PubMed ID: 35339272
    [No Abstract]   [Full Text] [Related]  

  • 24. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 and autoimmune phenomena: Vitiligo after Astrazeneca vaccine.
    López Riquelme I; Fernández Ballesteros MD; Serrano Ordoñez A; Godoy Díaz DJ
    Dermatol Ther; 2022 Jul; 35(7):e15502. PubMed ID: 35393710
    [No Abstract]   [Full Text] [Related]  

  • 26. Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review.
    Pauluzzi M; Stinco G; Errichetti E
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e257-e259. PubMed ID: 34928518
    [No Abstract]   [Full Text] [Related]  

  • 27. COVID-19 mRNA vaccine safety, immunogenicity, and effectiveness in a hospital setting: confronting the challenge.
    Sultana J; Caci G; Hyeraci G; Albano L; Gianfredi V
    Intern Emerg Med; 2022 Mar; 17(2):325-327. PubMed ID: 35084646
    [No Abstract]   [Full Text] [Related]  

  • 28. Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.
    De Domingo B; López M; Lopez-Valladares M; Ortegon-Aguilar E; Sopeña-Perez-Argüelles B; Gonzalez F
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.
    Pitlick MM; Joshi AY; Gonzalez-Estrada A; Chiarella SE
    Allergy Asthma Proc; 2022 Jan; 43(1):40-43. PubMed ID: 34983709
    [No Abstract]   [Full Text] [Related]  

  • 30. A case of psoriatic spondyloarthritis exacerbation triggered by COVID-19 messenger RNA vaccine.
    Ohmura S; Hanai S; Ishihara R; Ohkubo Y; Miyamoto T
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e427-e429. PubMed ID: 35176180
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
    Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
    J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
    [No Abstract]   [Full Text] [Related]  

  • 32. COVID-19 mRNA Vaccines During Pregnancy: New Evidence to Help Address Vaccine Hesitancy.
    Kharbanda EO; Vazquez-Benitez G
    JAMA; 2022 Apr; 327(15):1451-1453. PubMed ID: 35325030
    [No Abstract]   [Full Text] [Related]  

  • 33. Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.
    Weiss SR
    JAMA; 2022 May; 327(20):2019-2020. PubMed ID: 35608592
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis.
    Kouhpayeh H; Ansari H
    Int Immunopharmacol; 2022 Aug; 109():108906. PubMed ID: 35671640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura.
    Chanut M; Jaidi R; Kohn M; Grange T; Brones C; Lombion N; Rousselot P; Longval T
    Platelets; 2022 May; 33(4):652-653. PubMed ID: 35225144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.
    Oster ME; Shay DK; Shimabukuro TT
    JAMA; 2022 May; 327(20):2020-2021. PubMed ID: 35608588
    [No Abstract]   [Full Text] [Related]  

  • 37. A Case of Myocarditis Presenting With a Hyperechoic Nodule After the First Dose of COVID-19 mRNA Vaccine.
    Park S; You J
    J Korean Med Sci; 2022 Apr; 37(16):e131. PubMed ID: 35470603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
    Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
    JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
    Holzworth A; Couchot P; Cruz-Knight W; Brucculeri M
    Kidney Int; 2021 Aug; 100(2):463-464. PubMed ID: 34048824
    [No Abstract]   [Full Text] [Related]  

  • 40. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
    Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A
    J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.